Search results with tag "Sunitinib"
DRUG NAME: SUNItinib - BC Cancer
www.bccancer.bc.caSUNItinib DRUG NAME: SUNItinib SYNONYM(S): SU11248, 1 SUNItinib malate 2 COMMON TRADE NAME(S): SUTENT® CLASSIFICATION: tyrosine kinase inhibitor Special pediatric considerations are noted when applicable, otherwise adult provisions apply.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET 1. PRODUCT NAME SUTENT (sunitinib 12.5mg capsules) SUTENT (sunitinib 25 mg capsules) SUTENT (sunitinib 37.5 mg capsules)
For the Patient Sunitinib - BC Cancer
www.bccancer.bc.caFor the Patient: Sunitinib : Other names: SUTENT® • Sunitinib (soo-NI-ti-nib) is a drug that is used to treat different types of cancer. It is a
CYP3A4 Inhibitor/Inducer Drug-drug Interactions for all ...
oncologypro.esmo.orgSunitinib - - If co-administration with a strong CYP3A4 inhibitor cannot be avoided, consider reducing the sunitinib dose to a minimum of 37.5 mg daily for GIST and
CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS …
mpha.in1touch.orgSUNItinib Temozolomide Temsirolimus Teniposide Thalidomide Thioguanine Thiotepa Topotecan ValGANciclovir 3 Valrubicin ... only the parent compound is listed, handle all derivatives of a hazardous drug the same as the parent compound. Radioactive pharmaceuticals: nuclear medicine has policies and procedure for safe handling of radioactive ...
Oral Health Management of Patients at Risk of Medication ...
www.sdcep.org.uksunitinib Sutent® aflibercept Zaltrap® Drug Type Drug Name Trade Name(s) Drugs Associated with MRONJ Prescribed in the United Kingdom* Introduction Is the patient currently taking a bisphosphonate drug or have they taken one in the past? YES Is the patient currently taking denosumab or have they taken denosumab in the last nine months? NO ...
Patient Support Program & Patient Assistance Enrollment Form
www.pfizeroncologytogether.comthe patient’s experience with Pfizer products, services, and programs Patients Eligible for the Pfizer Patient Assistance Program To qualify for free medicine, the patient must meet certain financial requirements, as well as meet the criteria below: ... SUTENT® (sunitinib malate)
prescribing information for AFINITOR/AFINITOR DISPERZ ...
www.novartis.uswith sunitinib or sorafenib. (1.3) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and …
Biología molecular del cáncer y las nuevas herramientas en ...
www.medigraphic.comel sunitinib y el pazopanib, que son otros inhibidores de tirosincinasa con actividad en diferentes vías de señalización, y el trastuzumab y el ... levels, with the consequent death of the patient. Hanahan and Weinberg described the hallmarks or features of cancer, such as the
Oral Health Management of Patients at Risk of Medication ...
www.sdcep.org.uksunitinib vastin® ® that ept ap® Drug Type Drug Name Trade Name(s) Drugs Associated with MRONJ Prescribed in the United Kingdom* oduction Is the patient currently taking a bisphosphonate drug or have they taken one in the past? YES Is the patient currently taking denosumab or have they taken denosumab in the last nine months? NO
CANCER DRUG PHARMACOLOGY TABLE
www.bccancer.bc.cadrugs by their target, such as EGFR-inhibitors or multikinase inhibitors for oral drugs with multiple targets (e.g., pazopanib,sorafenib, sunitinib). abemaciclib (CDK 4/6) acalabrutinib (BTK) afatinib (EGFR, HER2, HER4) AGS-16C3F (MMAF) (antibody conjugated with cytotoxic) alectinib (ALK) alemtuzumab (CD52) amivantamab (low-fucose IgG1 bispecific
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eu4 Hepatic impairment No starting dose adjustment is recommended when administering sunitinib to patients with mild or moderate (Child-Pugh class A …
DRUG NAME: Pazopanib - BC Cancer
www.bccancer.bc.caSimilar to sunitinib or sorafenib, pazopanib is reported to block tumour growth by interfering with angiogenesis. Pazopanib is also an inhibitor of fibroblast growth factor receptor (FGFR-1 and -3), the interleukin receptor (IL-2), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). 3-5. PHARMACOKINETICS: Oral Absorption 14-39%
Sunitinib介紹 - taiwan-pharma.org.tw
www.taiwan-pharma.org.tw第26卷第3期 Sep. 30 2010 Sunitinib介紹 藥學雜誌 第104冊 133 發劑一起併用是不是需要調整劑量？ 有研究指出當sunitinib與ketoconazole